AAV2 variant (Y272F, Y444F, Y500F, Y730F) Rep-Cap plasmid (retina-validated serotype AAV-RC plasmid) (Amp and Kanamycin) (GeneMedi Owned)

GeneMedi's AAV2 variant (Y272F, Y444F, Y500F, Y730F) Rep-Cap plasmid supplies the AAV2 Rep (replication) proteins and the AAV2 variant (Y272F, Y444F, Y500F, Y730F) capsid protein.

You can produce AAV2 variant (Y272F, Y444F, Y500F, Y730F) particle in 293T cell line in high titer using GeneMedi's AAV2 variant (Y272F, Y444F, Y500F, Y730F) Rep-Cap plasmid with GM's AAV expression vector (overexpression or shRNA) and AAV helper plasmid.

The tissue tropism of AAV2 variant (Y272F, Y444F, Y500F, Y730F) vector has been validated in retina (retinal ganglion cells) by both intravitreal injection and sub-retinal injection., with potential applications in retina gene therapy.

GeneMedi offers both Ampicillin (Amp) resistance and Kanamycin (Kan) resistance for the AAV Rep-Cap Plasmids.

Target products collectionGo to AAV vector system >>

pdfMap Download

Product Description

Cat.NO Product Name Organization Type Price(In USD)
P-RC04 AAV2 variant (Y272F, Y444F, Y500F, Y730F) Rep-Cap Plasmid (Amp resistance)
Size：5ug 		Academic 1719
P-RC04 AAV2 variant (Y272F, Y444F, Y500F, Y730F) Rep-Cap Plasmid (Amp resistance)
Size：5ug 		Biotech & Pharma & Medical Device & Diagnostics
P-RC04 AAV2 variant (Y272F, Y444F, Y500F, Y730F) Rep-Cap Plasmid (Amp resistance)
Size：5ug 		CRO&CDMO&
CXO&CMC&
Manufacturing company
P-RC04 AAV2 variant (Y272F, Y444F, Y500F, Y730F) Rep-Cap Plasmid (Amp resistance)
Size：≥10mg 		All
P-RC04-Kan AAV2 variant (Y272F, Y444F, Y500F, Y730F) Rep-Cap Plasmid (Kan resistance)
Size：≥10mg 		All
P-PK04 AAV2 variant (Y272F, Y444F, Y500F, Y730F) Vector System (Amp resistance)
1. AAV2 variant (Y272F, Y444F, Y500F, Y730F) Rep-Cap Plasmid, 5ug
2. AAV Helper Plasmid, 5ug
3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug
 Academic 3024
P-PK04 AAV2 variant (Y272F, Y444F, Y500F, Y730F) Vector System (Amp resistance)
1. AAV2 variant (Y272F, Y444F, Y500F, Y730F) Rep-Cap Plasmid, 5ug
2. AAV Helper Plasmid, 5ug
3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug
Biotech & Pharma & Medical Device & Diagnostics
P-PK04 AAV2 variant (Y272F, Y444F, Y500F, Y730F) Vector System (Amp resistance)
1. AAV2 variant (Y272F, Y444F, Y500F, Y730F) Rep-Cap Plasmid, 5ug
2. AAV Helper Plasmid, 5ug
3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug
CRO&CDMO&
CXO&CMC&
Manufacturing company
P-PK04 AAV2 variant (Y272F, Y444F, Y500F, Y730F) Vector System (Amp resistance)
1. AAV2 variant (Y272F, Y444F, Y500F, Y730F) Rep-Cap Plasmid, ≥10mg
2. AAV Helper Plasmid, ≥10mg
3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01-Kan), ≥10mg
 All
P-PK04-Kan AAV2 variant (Y272F, Y444F, Y500F, Y730F) Vector System(Kan resistance)
1. AAV2 variant (Y272F, Y444F, Y500F, Y730F) Rep-Cap Plasmid(Kan resistance), ≥10mg
2. AAV Helper Plasmid(Kan resistance), ≥10mg
3. pGMAAV-CMV-MCS-T2A-ZsGreen (Kan resistance) (P-AAVV-B01-Kan), ≥10mg
 All
GeneMedi offers both seed and amplification services for the Amp-resistant AAV Rep-Cap Plasmid.
GeneMedi only offers amplification services and do not provide seed for the Kan-resistant AAV Rep-Cap Plasmid currently.
If you want to obtain higher quantities of plasmids (mg), please visit GM TransExcellent Plasmid DNA Rapid Preparation Service.
Terms of sale:
For Seed (5ug):
The purchaser may not reverse engineer this product to extract the sequence for independent use. The purchaser may not transfer this product to others for manufacturing purposes. The purchaser may not use this material to manufacture this product for any other party.

For plasmid production& amplification (≥10mg):
The purchaser may not reverse engineer this product to extract the sequence for independent use. The purchaser may not transfer this product to others for manufacturing purposes. The purchaser may not use this material to manufacture this product for themselves or any other party.

Citation

Title Publication Date
Rhythmic Cilia Changes Support SCN Neuron Coherence in Circadian Clock Science 2023/6/2
Hepatocyte-specific Mas activation enhances lipophagy and fatty acid oxidation to protect against acetaminophen-induced hepatotoxicity in mice Journal of Hepatology 2022/11/8
MED1 Regulates BMP/TGF-β in Endothelium: Implication for Pulmonary Hypertension Circulation Research 2022/10/14
WWC proteins mediate LATS1/2 activation by Hippo kinases and imply a tumor suppression strategy MOLECULAR CELL 2022/4/15
E3 ubiquitin ligase RNF5 protects against hepatic ischemia reperfusion injury by mediating PGAM5 ubiquitination HEPATOLOGY 2021/11/8
PEG-mediated transduction of rAAV as a platform for spatially confined and efficient gene delivery Biomaterials Research 2022/12/2
Loss of CLDN5 in podocytes deregulates WIF1 to activate WNT signaling and contributes to kidney disease Nature Communications 2022/3/24
Fibroblast-derived CXCL14 aggravates crystalline silica–induced pulmonary fibrosis by mediating polarization and recruitment of interstitial macrophages Journal of Hazardous Materials 2023/9/8
Tumor-derived lactate promotes resistance to bevacizumab treatment by facilitating autophagy enhancer protein RUBCNL expression through histone H3 lysine 18 lactylation (H3K18la) in colorectal cancer Autophagy 2023/8/29
TNFAIP2 confers cisplatin resistance in head and neck squamous cell carcinoma via KEAP1/NRF2 signaling Journal of Experimental & Clinical Cancer Research 2023/8/1


Validation data

transduction of AAV2 variant (Y444F) vector system in mouse retina
Figure. Selected transduction results of AAV2 variant(Y444F) vector system in mouse retina.

Virus and titer: AAV2 variant(Y444F) vector system, 1×1012 vg/ml
Animal: mouse, C57, 2 months
Infection site: retina
Gene delivery method: subretinal cavity injection, 3μl
Determine assay: 3 weeks post infection, wholemount, immunofluorescence microscopy


Associated products and services


Products & Service Products & Service Information
AAV Packaging service Detail
Promise-ORF™ viral CDNA library Detail
Plasmid DNA Rapid Preparation Service Detail